The company is not developing an mRNA vaccine, but had been using one as the control in a 10,000-subject Phase IIb trial.

Dave Miller, PhD, discusses how tailored solutions, trust, and lifecycle planning are redefining partnerships in bio/pharmaceutical development.

The scaled adoption of cell and gene therapies demands a new era of agile, precise, and efficient quality control methods.

The new targeted pipeline will advance Nxera’s oral GLP-1 agonists, novel GPCR targets, and structure-based drug design to ...

Thermoplastic elastomers (TPE) offer a PFAS-free solution for stoppers in parenteral packaging, ensuring a safer and more ...

FDA reinstates Vinay Prasad to lead CBER as gene therapy safety concerns spotlight regulatory challenges in biotech manufacturing.

The company presented new data from its Alzheimer’s disease research efforts across its diagnostics and pharmaceutical ...

The agency’s new program is designed to increase regulatory predictability and streamline review of domestic manufacturing ...

The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial ...

Radiopharmaceuticals are moving from their standard use of treating superficial tumors into radio drug conjugates that target ...

For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

Jerry Keybl, senior vice-president, Biopharma Products and Strategy, Avantor, discusses innovations in biomanufacturing and ...